All faculty and staff received a letter yesterday explaining significant changes to the HMO2 health insurance plan for 2007. Town hall meetings are scheduled on the medical campus today (Tuesday) to address any concerns or questions you may have about the health insurance plans. Here is the schedule:

7 to 8 a.m., Retter Auditorium, Bascom Palmer Eye Institute

Noon to 1 p.m., Medical Wellness Center, 13^th floor, Classroom C

5 to 6 p.m., Mailman Center, 8th-floor auditorium   

As a reminder, the Open Enrollment period has been extended through December 1, 2006.

Joyce M. Slingerland, M.D., Ph.D., director of the Braman Family Breast Cancer Institute at the UM/Sylvester Comprehensive Cancer Center, has been honored with one of the nation's most prestigious funding awards for her novel cancer research. She was one of only five investigators in the nation, in any medical discipline, to receive a Doris Duke Distinguished Clinical Scientist Award.

"This is an extraordinary honor for Dr. Slingerland and we are very proud of her and her work," says Pascal J. Goldschmidt, M.D., dean of the Miller School of Medicine. "Many distinguished colleagues have applied over the years and have failed to reach the award, underscoring the formidable achievement for Joyce. The discoveries made by the Braman Family Breast Cancer Institute are leading us in promising new directions for cancer prevention and treatment."

The Doris Duke award honors physician-scientists with $1.5 million in funding over five years. At UM/Sylvester, the funding will support Slingerland's groundbreaking work investigating how estrogen affects the action of a key cell cycle inhibitor, p27, to regulate breast cancer cell proliferation.

The Doris Duke Charitable Foundation solicited two nominations from each medical school in the nation. From that potential pool of about 300 candidates, only 15 were asked to come for interviews, and only five were selected for the award. The $300,000 yearly award supports work to narrow the gap between basic biomedical research and its clinical application through two major initiatives: advancing promising science into real-world patient treatments, and training the next generation of scientists.

"While I personally strive for excellence in my own research, I'm cognizant that my potential impact on science in the future is more likely to be manifest through the people that I have the privilege to train," Slingerland said.

Ambassadors have worked hard around campus, encouraging individuals to give. “They are the best ambassadors in the world,” says Dean Pascal J. Goldshmidt, M.D. "But we are not there yet; we have reached about 50 percent of  the goal for the medical campus."

As a reminder, you can designate funds to a UM program of your choice, including the Momentum Campaign. Please remember that every gift is important, and that collectively we can make a difference in our community.

Log on to www.myUM.miami.edu and make your gift  today. For more information, call 305-243-3453 or write communityrelations@med.miami.edu.

Please bring completed forms to the table outside Au Bon Pain restaurant from 11 a.m. to 1 p.m. this coming Thursday; Tuesday, November 21; and Tuesday, November 28. Tickets also may be picked up at  the Schoninger Quadrangle on Thursday, November 30,  from 11 a.m. to 1 p.m. For more information, call 305-284-2263.

Because the contribution you set aside for this program is deducted from your salary before taxes, the money you use to pay for these expenses is always tax free and interest free. For example, if you pay $100 per month for prescription drugs, you can save approximately $272 each year in taxes just by placing the money in a pre-tax health care FSA (based on a 22.65 percent tax rate).

Learn more about FSAs by calling the Humana Open Enrollment Hotline at 1-888-393-6765. You may also contact Humana's Open Enrollment Hotline via e-mail at oe@humana.com. 

The Division of Pediatric Neurosurgery specializes in the treatment of infants with hydrocephalus, vascular disorders, head and spine injuries, tumors of the brain and spine, epilepsy, myelomeningocele, and other congenital malformations. For more information about the new location or to schedule an appointment, call 305-662-8386.

To save time, print and fill out the consent form found at this link: http://www6.miami.edu/UMH/CDA/UMH_Main/1,1770,2531-1;50591-3,00.html, then bring the form with you to receive your shot. You do not need an appointment and the vaccine is free to all employees. The supply is limited, so don’t miss your chance.

This course offers coaching skill training to managers who supervise Leadership Academy participants. Please register at www.netlearning.miami.edu. For more information, call 305-243-3090.

Vendors will pay $100 to present menus and portfolios, and offer ideas for  upcoming UM events. All contributions will go to the United Way. For more information, please contact DeeDee Wise at 305-243-3662.  

How our values help us set goals and prioritize activities will be the focus of the session, which is part of the Professional Development course series. 

Please register at www.netlearning.miami.edu. For more information, call 305-243-3090.

The Center for Liver Diseases is recruiting participants for the following studies:

• Patients with chronic liver disease
This studies the correlation between liver histology and elasticity measured in patients with chronic liver disease using a device known as Fibroscan. This is a painless, non-invasive test. Qualifying patient must have received a laparoscopic liver biopsy within the past two months or scheduled a laparoscopic liver biopsy within the next two months by their PCP at Cedars Medical Center-Miami. This is a one time visit. Liver cancer patients are excluded. Contact: Zvi Leibovici at 305-243-2330 or zleibovici@med.miami.edu.

• Determining the relation of an elevated HBV DNA in Hepatitis B patients
This is a chart review on hepatitis B subjects to determine the relation of an elevated HBV DNA and normal liver function tests to the histological findings of the liver biopsy. The study requires the subject has a previous liver biopsy between 2003-2006. They must also see the research team to obtain a hepatitis B serology panel, liver function tests (ALT and AST), and HBV viral load. Subjects must be more than 18 years old, have a documented laboratory diagnosis of HBV infection of at least six months, treatment naïve patient, and a documented HBV DNA. For further information, contact Zvi Leibovici at 305-243-2330, or e-mail at zleibovici@med.miami.edu.

• Patients with cirrhosis of the liver as a result  of Hepatitis B 
This is a phase III b protocol comparing entecavir vs. adefovir in chronic hepatitis B subjects with evidence of hepatic decompensation. Subjects must have cirrhosis because of hepatitis B infection, never been treated for hepatitis B or treated with lamivudine (epivir) only, and do not have HIV, hepatitis C or D. For further information please call: 305)-243-6939, or e-mail the study  coordinator, Connie Higgins at: chiggins@med.miami.edu.

• Patients with hepatic encephalopathy
This study will compare Lactulose and Rifaximin to determine the benefit of either drug, or a combination of both. We will be enrolling patients with cirrhosis of the liver and a history of a previous hospitalization for hepatic encephalopathy. Patients will be followed for six months and a one-month post-treatment. Contact Macy Ho, CRC 305-243-4648 or e-mail Mho@med.miami.edu.

• Patients with chronic liver disease
This studies the correlation between liver histology and elasticity measured in patients with chronic liver disease using a device known as Fibroscan. This is a painless, non-invasive test. Qualifying patient must have received a laparoscopic liver biopsy within the past two months or scheduled a laparoscopic liver biopsy within the next two months by their PCP at Cedars Medical Center-Miami. This is a one time visit. Liver cancer patients are excluded. Contact: A. Brown at 305-243-2184 or abrown@med.miami.edu

• Vaccine test in patients with chronic hepatitis C
The Center for Liver Diseases is conducting a phase I, double-blind, placebo controlled, dose escalation, multi-center trial of a therapeutic vaccine in patients with chronic hepatitis C infection. Subject must be > 18, have no hypersensitivity to baker's yeast, non-cirrhotic, compensated liver disease, and must have received a liver biopsy within the past two years or be willing to have one performed. Subjects can be naïve to previous treatment, or a relapser or partial responder to an interferon-based treatment. Must meet other criteria as well. Contact Macy Ho at 305-243-4648 or mho@med.miami.edu.

• Study of three treatments
The Center for Liver Diseases is conducting a phase 2, double-blind, multi-center, randomized research study in HBV decompensated subjects. Adult subjects with CPT score of 7-12 and no history of HCC will be assigned to one of the three treatment arms: tenofovir disoproxil fumarate (TDF), emtricitabine plus tenofovir disprocil fumarate (FTC/TDF) or entecavir (ETV). Patients can be on lamivudine or adefovir dipivoxil. Must meet other criteria. Contact clinical research coordinator Karina Herrera at 305-243-2148 or at kherrera@med.miami.edu.

• Study of liver diseases
The Center for Liver Diseases is conducting a Phase II study for men and women, investigational oral medication for liver scarring caused by chronic Hepatitis C. Subjects must be between 40 and 70 years old, have been diagnosed with chronic Hepatitis C, have failed prior Hepatitis C therapy with interferon and ribavirin treatments, which must have been discontinued at least 12 months ago. Study staff will review additional criteria if you are interested in learning more. The study should last approximately 56 weeks with 14 clinic visits. Contact Macy Ho, CRC 305-243-4648 or Mho@med.miami.edu

Do you or does someone you know experience pain related to spinal cord injury? Eva Widerström-Noga, Ph.D., and her colleagues are conducting research into the nature and treatment of pain associated with spinal cord injury. Studies are enrolling now.  Eligible participants will be 18 to 70 years of age and at least two years post-injury.  If you are interested in enrolling, please call The Miami Project to Cure Paralysis at 305-243-8132 for information.

Heather Woolery-Lloyd, M.D., of the Division of Cosmetic Dermatology, is looking for people between the ages of 18 and 39 who have mild to severe acne to participate in a research study to determine whether use of an investigational topical treatment will improve acne.  If you are interested, please contact a member of the research staff at 305-531-5788.

The Department of Psychology is recruiting participants for the following studies:

• A schizophrenia family study 
Have you or one of your relatives been diagnosed with schizophrenia or schizoaffective disorder? Are you in regular contact with this person? If so, you and your family may be eligible to participate in a free family-focused treatment research study. During the treatment, clinicians will provide factual information about schizophrenia and schizoaffective disorder. In addition, techniques to assist the family in coping with mental illness will be presented. Treatment is available in English and Spanish. If interested, please contact the Schizophrenia Family Project at 305-284-5455.

• A family factors and autism study
The aim of this project is to better understand families’ emotional reactions to autism spectrum disorders. We seek the participation of adults with high-functioning autism or Asperger’s and one of his or her parents. Participation will involve one hour-long telephone call. If you would like to help with this study or if you have any questions, please contact Stephanie Wasserman at 305-284-2307.

Researchers at the MRI Center need healthy subjects for a magnetic resonance imaging study. For more information, please visit http://midas.med.miami.edu/Research/MRStudies.htm.

Patients with idiopathic pulmonary fibrosis (IPF) are being recruited for a study of effects of sildenafil on exercise and breathlessness. Participants must have a firm clinical diagnosis of IPF, be 40 to 85 years of age, and not be on medication for IPF. Interested patients or physicians wishing to refer patients should call 305-575-3548, fax 305-575-3126, or e-mail rjackson2@med.miami.edu.

The Department of Obstetrics and Gynecology is testing experimental medications and therapies for the treatment of cervical dysplasia, a pre-cancerous condition that can lead to cancer if left untreated. Current treatments are surgical or invasive. This study is testing an investigational gene therapy to see if it safely and effectively treats HPV medicated cervical lesions as a result of dysplasia. If you are between 18 and 25 and have had an abnormal PAP test, you may be able to take part in this research study. Qualified participants will receive all study-related care and study therapy. To find out more, call Iliana Rivas at (305) 243-5832 or i.rivas@miami.edu

The Department of Psychology and the Division of Cancer Prevention and Control is conducting a quality of life research intervention with advanced prostate cancer patients. Participants should have Stage III or IV prostate cancer and have recently or currently been treated with hormone therapy. Eligible participants will take part in a ten-week cognitive behavioral stress and affect management program or a health promotions program. Three psychosocial/medical assessments are also required. If you are interested in this study or would like more information, please contact Frank Penedo, Ph.D., at 305-243-3329, or fpenedo@miami.edu.

Daniel Santisteban, Ph.D., of the Center for Family Studies in the Department of Psychiatry and Behavioral Sciences, is currently conducting a research program that would provide adolescents and/or their family treatment for free. Participants must be 14 to 17 years old, have a parent or legal guardian willing to participate, meet DSM criteria for both substance abuse disorder and borderline personality disorder, and be willing to participate in four separate but paid evaluations. If interested, please contact Henry Calderon, clinical research specialist/assessor, at 305-243-2225, or hcalderon@med.miami.edu for details.

The Center for Research and Education on Aging and Technology Enhancement is conducting research with family caregivers of dementia patients who speak English and are 50 years of age or older. If you are not a caregiver but are interested in participating, you may be able to help as well. Participants will receive basic training on how to use the Internet and will be asked to look for information about care-giving and dementia. If you are interested in being a part of this research study, please call 305-355-9200. You will be paid for your time and effort.

Jennifer B. Marks, M.D., is currently recruiting patients ages 18 through 40 with type 1 diabetes mellitus with a recent diagnosis for participation in a research study to test the safety and effectiveness of an investigational medication. Patients must be taking multiple insulin injections daily and in good health. Those who are interested should contact Rogelio Suarez at 305-243-6573 or rsuarez2@med.miami.edu.

The AIDS Clinical Research Unit, directed by Margaret Fischl, M.D., is recruiting participants for the following studies:

• A phase I IL-7 study (IL-7 is a cytokine that aids T-cell development and improves T-cell survival). Participants must be 18 to 50 years of age, receiving antiretroviral therapy for at least 12 months, have an HIV-1 RNA level less than or equal to 50,000 copies/ml, and have a CD4 cell count of 100 cells/ccm or higher. Participants must be willing to do 12-hour IL-7 blood level monitoring. Up to $200 in food certificates provided.

• An investigational CC-chemokine receptor 5 (CCR5) entry inhibitor for patients with HIV. The study will look at single dose, dose escalations of a study drug (0.5 mg, 2.0 mg and 5.0 mg) and a placebo. The study will determine how well the study drug blocks CCR5 receptors and is tolerated. Participants must be 18 and older, not taking antiretroviral therapy for at least three months and have a viral load greater than 5,000 and a CD4 count greater than 250. Must be willing to do six-hour drug level monitoring. Up to $250 provided.

For more information on studies conducted by the AIDS Clinical Research Unit, contact Juan at 305-243-3838 or Leslie at L.Thompson@miami.edu.

The SPARE Study (Soy Phytoestrogens As Replacement Estrogen) is currently recruiting women 45 to 60 years of age to study the role of soy phytoestrogens given in tablet form to prevent bone loss. Participants will be given a physical exam at study entry, an annual mammogram and bone density test, and will be asked to come for 10 study visits over a period of two years for blood tests and to complete questionnaires about diet, exercise, and well-being. Interested women should contact the SPARE Study Office at 305-243-4330 or via e-mail at aherrin@med.miami.edu.

The University of Miami Skin Research Group, directed by Brian Berman, M.D., Ph.D., is looking for people with acne, atopic dermatitis (eczema), and keloids. Participants should be 18 or older for the acne and keloid studies and ages 2 to 17 for the atopic dermatitis studies. If interested, please contact the research staff at 305-243-5519 or visit our website at http://www.skininvestigation.com/.

Bruce Rubin, M.D., is currently performing a study on trigeminal neuralgia (TN) treatment with subcutaneous injections of BOTOX® to evaluate the effectiveness of treating facial pain associated with TN. Patients must have a diagnosis of TN for more than three months and be at least 18 years of age.
 
Dr. Rubin is also seeking patients for a research study on the treatment of tightness/spasticity in the wrist, fingers, and elbow caused by a stroke while evaluating the effect of BOTOX® on pulmonary functioning. Patients must be 18 years of age, have had a stroke six months ago or longer, have a pulmonary/breathing problem and cannot have used BOTOX® or any other botulinum toxin previously for any condition. Please contact Amy L. Kaye, ARNP, at 305-243-6223 for additional information on either of these studies.